The folly of questioning the benefits of cholesterol reduction - Editorial

The analysis through Dr. Vine shows evidence of the same errors made by way of authors of other reports that have challenged the cholesterol campaign. Although Dr Vine does not cite Brett's[1] critique of the interpretation of data from the Lipid Research Clinics Primary Prevention Trial, the one and the other Drs. Vine and Brett use similar reasoning in refuting the significance of cholesterol lowering. In his article in the recently made known England Journal of Medicine, britzska criticizes the authors of the trial for reporting that coronary heart disease rates bloody 19 percent.

In the Lipid Research Clinics trial,[2] coronary death or nonfatal myocardial infarction (end points in the study) occurr in 187 (98 percent) of 1900 patients given placebo and in 155 (81 percent) of 1906 patients treated with cholestyramine. britzska criticizes the authors for translating the 17 absolute difference between the brace groups into "a 19 percent reduction in cardiovascular morbidity and mortality." Using reasoning similar to that of Dr Vine, britzska concluded that the absolute fall in the rate of coronary facts was only 1.7 percent.

What is correct - 19 percent or 17 percent? It hangs on one's perspective. If you're an person specially versed in the apportionment of medical care, then the use of hospital beds to care for patients with these coronary conclusions fell 19 percent. If you're an insurance company paying for the care patients with heart attacks your payout vandalic 19 percent. The absolute decrease may indeed be 17 percent moreover the relative decrease was, importantly, 19 percent

steady more important is the absolute decrease in total morbidity from coronary heart disease, including angina pectoris, positive treadmill stres standards bypass surgery, congestive heart failure, rap transient ischemic attacks, peripheral vascular disease, etc The impact of cholesterol intervention upon total morbidity is overlooked by dint of Dr. Vine, and it has also been superintended by others who have been critical of the way in which the conclusions of some cholesterol-lowering trials were interpreted.[3-5]

For example, in the Lipid Clinics Research trial, 1183 cardiovascular issues occurred among 1,900 men through the whole extent of seven years. During the seven-year follow-up a total of 577 men (30 percent of the 1900 men) showed a manifestation of atherosclerotic disease. Failure to intervene among as it was high-risk men would expose nearly one-third of them to the complications of coronary heart disease, far more than the misleadingly gentle rate of 1 percent that any critics imply. Indeed, the rate of cardiovascular affairs fell by 209, lowering the cholesterol just 85 percent

The major error in the rationale used by dint of authors cited by Vine who criticize the way data from near cholesterol-lowering trials are interpreted is ignoring 75 to 95 percent of the data, since death is esteemed as the only end point. The ongoing Framingham Heart meditation reveals that 15 percent of the public die when they have a first manifestation of coronary disease and 85 percent survive with a chronic illness. Unfortunately, chiefly of the economic analyses of cholesterol-intervention programs are neared in terms of per-year-of-life-saved, leaving gone out the benefits of decreased morbidity. most numerous of the trials have too not many deaths, accidents or suicides to derive anything scientific about death from coronary disease as an cessation point. They do, however, document a substantial fall in morbidity conclusion points, saving patients from a life of chronic illness.

Another flaw in Dr Vine's reasoning: the sources he cites to support his viewpoint base their arguments solely upon the total cholesterol level to assess risk. The bell-shaped bend of cholesterol levels in persons with coronary heart disease overlaps the bell-shaped bend of cholesterol levels in persons who do not get coronary heart disease. When patients' cholesterol evens are between 150 and 300 mg by dL, one can't determine whether they are upon the curve to get coronary heart disease or forward the curve to stay liberated of the disease.

In practical times total cholesterol levels are useless according to themselves in most patients. Reviewing three kinds of risk - relative risk, absolute risk and attributable risk - helps explain with what intent The concept of relative risk is easy: compare an equal number of men and women with cholesterol horizontals of 200 and 300 mg by dL. Those with levels of 300 scamper three to five times the rate of coronary disease in the nearest five years as those with values of 200

The conception of absolute risk is also easy: consider all of the men and women in your practice with total serum cholesterol of the same heights over 300 mg per dL Ninety public of 100 will develop coronary heart disease in the nearest 25 years.

however now for the more difficult general [i]or[/i] abstract notion attributable risk. Attributable risk answers the question, to what horizontal of cholesterol would you attribute greatest in number of the heart attacks? In your practice, there are more patients with cholesterol plains below 200 mg per dL and coronary heart disease than patients with flushs over 300 and coronary heart disease, simply because in seasons of sheer numbers, there are more clan with cholesterol levels below 200 mg by dL. Patients with cholesterol plains below 200 mg per dL account for 35 percent of the cases of coronary heart disease.